Vir Biotechnology, Inc. (VIR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VIR SEC filings page.
Vir Biotechnology, Inc. (VIR) reported $68.6M in revenue for fiscal year 2025, down 7.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
By FY2025, Vir was an R&D-heavy development business, with $68.6M of revenue, large losses, and cash outflow tracking investment.
The business’s sharp break after FY2022 appears in both earnings and cash: operating cash flow moved from$1.7B to-$391.8M by FY2025, so the earlier cash result was not a dependable operating baseline. In FY2025, a net loss of$438.0M sat close to operating cash flow of-$391.8M , indicating losses were translating into cash use rather than being mostly noncash accounting effects.
Assets fell from
FY2025 R&D was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Vir Biotechnology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Vir Biotechnology, Inc. held $775.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $391.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Vir Biotechnology, Inc. scores 49/100 among other emerging companies.
Vir Biotechnology, Inc. had 140M shares outstanding at the end of fiscal year 2025, against 137M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Vir Biotechnology, Inc. scores 66/100 among other emerging companies.
Vir Biotechnology, Inc. spent $456.0M on research and development in fiscal year 2025, which was 83.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Vir Biotechnology, Inc. scores 99/100 among other emerging companies.
Vir Biotechnology, Inc. reported revenue of $68.6M in fiscal year 2025, against $74.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Vir Biotechnology, Inc. scores 29/100 among other emerging companies.
Vir Biotechnology, Inc.'s operations used $391.8M of cash in fiscal year 2025, against $446.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Vir Biotechnology, Inc. scores 72/100 among other emerging companies.
Vir Biotechnology, Inc.'s cash, cash equivalents and investments came to $775.5M at the end of fiscal year 2025, against $237.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Vir Biotechnology, Inc. scores 83/100 among other emerging companies.
Vir Biotechnology, Inc. scores 2.32, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.0B) relative to total liabilities ($237.5M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vir Biotechnology, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Vir Biotechnology, Inc. reported a net loss of $438.0M while operations used $391.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Vir Biotechnology, Inc. generated $238.9M in revenue in Q2 2026. This represents an increase of 19582.5% from the same quarter a year earlier.
Vir Biotechnology, Inc.'s EBITDA was $76.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 165.9% from the same quarter a year earlier. Against the prior quarter it is up 158.8%.
Vir Biotechnology, Inc. reported $80.1M in net income in Q2 2026. This represents an increase of 172.2% from the same quarter a year earlier. Against the prior quarter it is up 163.7%.
Vir Biotechnology, Inc. earned $0.47 per diluted share (EPS) in Q2 2026. This represents an increase of 158.8% from the same quarter a year earlier. Against the prior quarter it is up 155.3%.
Cash & Balance Sheet
Vir Biotechnology, Inc. generated $123.3M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 200.4% from the same quarter a year earlier. Against the prior quarter it is up 192.9%.
Vir Biotechnology, Inc. held $278.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Vir Biotechnology, Inc.'s gross margin was 100.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the same quarter a year earlier.
Vir Biotechnology, Inc.'s operating margin was 30.8% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Vir Biotechnology, Inc.'s net profit margin was 33.5% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Vir Biotechnology, Inc.'s ROE was 8.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 19.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 23.6 percentage points.
Capital Allocation
Vir Biotechnology, Inc. invested $135.3M in research and development in Q2 2026. This represents an increase of 38.7% from the same quarter a year earlier. Against the prior quarter it is up 24.2%.
Vir Biotechnology, Inc. invested $32K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 98.7% from the same quarter a year earlier. Against the prior quarter it is down 91.8%.
Not reported for Q2 2026.
VIR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $238.9M+19582.5% | N/A | $64.1M+417.8% | $240K-89.9% | $1.2M-60.5% | $3.0M-94.6% | $12.4M-26.3% | $2.4M-9.8% |
| Cost of Revenue | $0-100.0% | N/A | N/A | N/A | $11K-78.8% | $0-100.0% | $684K-14.3% | $50K+31.6% |
| Gross Profit | $238.9M+19762.5% | N/A | N/A | N/A | $1.2M-60.2% | $3.0M-94.6% | $11.7M-26.9% | $2.3M-10.4% |
| R&D Expenses | $135.3M+38.7% | $108.9M-8.2% | $88.3M-16.7% | $151.5M-22.4% | $97.5M-7.2% | $118.6M+18.5% | $106.1M-2.6% | $195.2M+34.6% |
| SG&A Expenses | $30.2M+35.5% | $23.3M-2.5% | $23.6M-11.6% | $22.2M-13.6% | $22.3M-26.4% | $23.9M-34.1% | $26.7M-35.2% | $25.7M-37.1% |
| Operating Income | $73.5M+162.0% | -$132.3M+5.2% | -$47.9M+59.1% | -$173.4M+25.0% | -$118.4M+25.4% | -$139.5M-74.3% | -$117.2M+15.7% | -$231.3M-23.9% |
| EBITDA | $76.2M+165.9% | -$129.5M+5.3% | -$44.9M+60.7% | -$170.5M+25.3% | -$115.5M+25.2% | -$136.7M-80.9% | -$114.2M+15.0% | -$228.4M-25.3% |
| Income Tax | $179K+5.3% | $170K+962.5% | -$137K-59.3% | $168K-5.1% | $170K+111.2% | $16K-94.2% | -$86K+98.2% | $177K+105.5% |
| Net Income | $80.1M+172.2% | -$125.7M-3.9% | -$42.9M+59.0% | -$163.1M+23.7% | -$111.0M+19.8% | -$121.0M-85.3% | -$104.6M+9.8% | -$213.7M-30.8% |
| EPS (Basic) | $0.48+160.0% | -$0.85+3.4% | -$0.30+60.5% | -$1.17+25.0% | -$0.80+21.6% | -$0.88-83.3% | -$0.76+11.6% | -$1.56-27.9% |
| EPS (Diluted) | $0.47+158.8% | -$0.85+3.4% | -$0.30+60.5% | -$1.17+25.0% | -$0.80+21.6% | -$0.88-83.3% | -$0.76+11.6% | -$1.56-27.9% |
| Diluted Shares (Avg) | 169M+22.0% | 147M+7.2% | N/A | 139M+1.7% | 138M+1.6% | 137M+1.6% | N/A | 137M+1.8% |
Not reported in any period shown, so not listed: Interest Expense.
VIR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+1.9% | $1.0B-21.6% | $1.0B-28.3% | $1.0B-32.0% | $1.2B-28.6% | $1.3B-27.1% | $1.4B-27.1% | $1.5B-26.7% |
| Current Assets | $573.7M-22.0% | $523.0M-43.9% | $514.1M-50.7% | $545.7M-47.9% | $735.7M-39.0% | $932.2M-23.2% | $1.0B-34.4% | $1.0B-40.8% |
| Cash & Equivalents | $278.7M+32.0% | $274.2M+0.2% | $232.2M+4.1% | $170.1M+1.0% | $211.1M-28.9% | $273.6M+70.2% | $222.9M-7.7% | $168.3M-62.8% |
| Short-Term Investments | $249.9M-35.5% | $196.3M-62.1% | $228.8M-66.3% | $327.8M-55.7% | $387.6M-54.4% | $517.4M-47.5% | $678.1M-46.7% | $740.6M-40.0% |
| Long-Term Investments | $475.0M+66.0% | $333.0M+52.6% | $314.6M+65.6% | $304.2M+12.1% | $286.1M+2.2% | $218.1M-39.4% | $190.0M+80.5% | $271.5M+585.3% |
| Goodwill | $16.9M0.0% | $16.9M0.0% | $16.9M0.0% | $16.9M0.0% | $16.9M0.0% | $16.9M0.0% | $16.9M0.0% | $16.9M0.0% |
| Total Liabilities | $232.3M-5.2% | $212.8M-19.4% | $237.5M-4.4% | $223.4M-13.3% | $245.1M+3.9% | $263.9M+7.0% | $248.4M-24.4% | $257.6M-30.3% |
| Current Liabilities | $95.0M-9.6% | $73.6M-46.4% | $92.8M-22.4% | $75.2M-35.8% | $105.0M+8.9% | $137.3M+45.9% | $119.7M-31.8% | $117.2M-29.0% |
| Non-Current Liabilities | $137.4M-1.9% | $139.3M+10.0% | $144.7M+12.4% | $148.1M+5.5% | $140.1M+0.4% | $126.6M-17.0% | $128.8M-16.1% | $140.5M-31.4% |
| Total Equity | $982.5M+3.7% | $812.8M-22.1% | $765.3M-33.5% | $796.1M-35.8% | $947.5M-33.9% | $1.0B-32.5% | $1.2B-27.7% | $1.2B-25.9% |
| Retained Earnings | -$1.2B-25.4% | -$1.3B-50.3% | -$1.2B-57.6% | -$1.2B-76.3% | -$991.7M-124.6% | -$880.7M-190.6% | -$759.8M-219.5% | -$655.2M-437.7% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
VIR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $123.3M+202.6% | -$132.4M-69.5% | -$25.9M+70.5% | -$167.6M+2.3% | -$120.2M-54.4% | -$78.1M+28.6% | -$87.6M+18.8% | -$171.5M-10.0% |
| Depreciation & Amortization | $2.7M-6.9% | $2.8M-2.0% | $2.9M+0.4% | $2.9M0.0% | $2.9M-31.0% | $2.9M-36.5% | $2.9M-35.6% | $2.9M-35.6% |
| Stock-Based Compensation | $12.4M-0.5% | $12.1M-14.0% | N/A | $11.4M-32.0% | $12.5M-43.8% | $14.1M-40.8% | N/A | $16.7M-38.0% |
| Capital Expenditures | $32K-98.7% | $390K-76.1% | $348K-82.6% | $317K-88.5% | $2.5M+281.1% | $1.6M-13.0% | $2.0M+30.0% | $2.8M-25.5% |
| Free Cash Flow | $123.3M+200.4% | -$132.8M-66.5% | -$26.2M+70.7% | -$167.9M+3.7% | -$122.8M-56.4% | -$79.7M+28.3% | -$89.6M+18.1% | -$174.2M-9.2% |
| Investing Cash Flow | -$197.1M-449.2% | $11.8M-90.7% | $86.7M-38.4% | $40.4M-65.9% | $56.5M-73.3% | $126.8M+346.2% | $140.7M+234.3% | $118.6M+301.2% |
| Financing Cash Flow | $78.4M+3730.7% | $162.5M+27077.8% | $1.0M-17.7% | $102K+229.0% | $2.0M-30.5% | $598K+293.4% | $1.3M-24.8% | $31K-88.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VIR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%+0.9pp | N/A | N/A | N/A | 99.1%+0.8pp | 100.0%+0.1pp | 94.5%-0.8pp | 97.9%-0.7pp |
| Operating Margin | 30.8% | N/A | -74.8% | -72267.9% | -9754.3% | -4602.5% | -946.7% | -9718.7% |
| Net Margin | 33.5% | N/A | -67.0% | -67975.4% | -9139.9% | -3989.6% | -845.2% | -8979.7% |
| Return on Equity | 8.2%+19.9pp | -15.5%-3.9pp | -5.6%+3.5pp | -20.5%-3.3pp | -11.7%-2.1pp | -11.6%-7.4pp | -9.1%-1.8pp | -17.2%-7.5pp |
| Return on Assets | 6.6%+15.9pp | -12.3%-3.0pp | -4.3%+3.2pp | -16.0%-1.7pp | -9.3%-1.0pp | -9.3%-5.6pp | -7.5%-1.4pp | -14.3%-6.3pp |
| Current Ratio | 6.04-1.0x | 7.11+0.3x | 5.54-3.2x | 7.25-1.7x | 7.01-5.5x | 6.79-6.1x | 8.71-0.3x | 8.94-1.8x |
| Debt-to-Equity | 0.240.0x | 0.260.0x | 0.31+0.1x | 0.28+0.1x | 0.26+0.1x | 0.25+0.1x | 0.220.0x | 0.210.0x |
| Asset Turnover | 0.20+0.2x | 0.000.0x | 0.06+0.1x | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.000.0x |
| FCF Margin | 51.6% | N/A | -40.9% | -69952.9% | -10111.8% | -2630.1% | -724.3% | -7321.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. VIR | FY2025 | $68.6M | -$438.0M | N/A | $2.0B | 66/100 |
| Prime Medicine, Inc. PRME | FY2025 | $4.6M | -$201.1M | N/A | $723.7M | 57/100 |
| ArriVent BioPharma, Inc. AVBP | FY2025 | N/A | -$166.3M | N/A | $824.9M | — |
| Tango Therapeutics, Inc. TNGX | FY2025 | $62.4M | -$101.6M | N/A | $4.0B | 65/100 |
| Day One Biopharmaceuticals, Inc. DAWN | FY2025 | $158.2M | N/A | N/A | $2.2B | 51/100 |
| KalVista Pharmaceuticals, Inc. KALV | FY2025 | N/A | -$183.4M | N/A | $1.4B | — |
Where Vir Biotechnology, Inc. Ranks
Frequently Asked Questions
What is Vir Biotechnology, Inc.'s annual revenue?
Vir Biotechnology, Inc. (VIR) reported $68.6M in total revenue for fiscal year 2025. This represents a -7.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vir Biotechnology, Inc.'s revenue growing?
Vir Biotechnology, Inc. (VIR) revenue declined by 7.6% year-over-year, from $74.2M to $68.6M in fiscal year 2025.
Is Vir Biotechnology, Inc. profitable?
No, Vir Biotechnology, Inc. (VIR) reported a net income of -$438.0M in fiscal year 2025.
What is Vir Biotechnology, Inc.'s EBITDA?
Vir Biotechnology, Inc. (VIR) had EBITDA of -$467.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Vir Biotechnology, Inc.'s gross margin?
Vir Biotechnology, Inc. (VIR) had a gross margin of 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Vir Biotechnology, Inc.'s return on equity (ROE)?
Vir Biotechnology, Inc. (VIR) has a return on equity of -57.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Vir Biotechnology, Inc.'s free cash flow?
Vir Biotechnology, Inc. (VIR) recorded an outflow of $396.6M in free cash flow during fiscal year 2025. This represents a 12.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vir Biotechnology, Inc.'s operating cash flow?
Vir Biotechnology, Inc. (VIR) recorded an outflow of $391.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Vir Biotechnology, Inc.'s total assets?
Vir Biotechnology, Inc. (VIR) had $1.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Vir Biotechnology, Inc.'s capital expenditures?
Vir Biotechnology, Inc. (VIR) invested $4.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Vir Biotechnology, Inc. spend on research and development?
Vir Biotechnology, Inc. (VIR) invested $456.0M in research and development during fiscal year 2025.
What is Vir Biotechnology, Inc.'s current ratio?
Vir Biotechnology, Inc. (VIR) had a current ratio of 5.54 as of fiscal year 2025, which is generally considered healthy.
What is Vir Biotechnology, Inc.'s debt-to-equity ratio?
Vir Biotechnology, Inc. (VIR) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vir Biotechnology, Inc.'s return on assets (ROA)?
Vir Biotechnology, Inc. (VIR) had a return on assets of -43.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Vir Biotechnology, Inc.'s P/E ratio?
Vir Biotechnology, Inc. (VIR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.0B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Vir Biotechnology, Inc.'s price-to-sales ratio?
Vir Biotechnology, Inc. (VIR) trades at 28.9x sales, its market capitalization divided by revenue of $68.6M revenue, FY2025. The market capitalization is $2.0B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Vir Biotechnology, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Vir Biotechnology, Inc. (VIR) held $775.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $391.8M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Vir Biotechnology, Inc.'s Altman Z-Score?
Vir Biotechnology, Inc. (VIR) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Vir Biotechnology, Inc.'s Piotroski F-Score?
Vir Biotechnology, Inc. (VIR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vir Biotechnology, Inc.'s earnings high quality?
Vir Biotechnology, Inc. (VIR) reported a net loss of $438.0M while operations used $391.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Vir Biotechnology, Inc.?
Vir Biotechnology, Inc. (VIR) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.